Antennova to Highlight P-I/II (CLINCH) Trial Data of ATN-022 to Treat Advanced/Metastatic Gastric Cancer at ASCO GI 2025
Shots:
- The company will highlight data from P-I/II (CLINCH) trial of ATN-022 to treat advanced/metastatic gastric cancer in Australia & China at ASCO GI 2025 under the title, ‘Safety and Preliminary Efficacy of ATG-022 in Patients with Advanced/Metastatic Gastric Cancer (CLINCH)’
- In the dose expansion phase (as of Nov 2024), 21 patients with CLDN18.2 expression IHC 2+ ≥20% had 42.9% ORR (9 PRs incl. 8 confirmed PRs, 11 SDs) & 95.2% DCR, while 10 patients with IHC 2+ <20% on 1.8–2.4mg/kg doses had 30% ORR (1 CR with durable response for over 14mos., 2 PRs) & 50% DCR
- ATN-022 showed a manageable safety, supporting further development. Enrollment for dose optimization & other solid tumors is ongoing in China & Australia
Ref: Antennova | Image: Antennova
Related News:- Yoltech Initiates a Dose-Escalation Study for YOLT-204 to Treat β -Thalassemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
